Login
LEXICON PHARMACEUTICALS, INC. logo

LEXICON PHARMACEUTICALS, INC.

lexpharma.com

What Do They Do?

Develops drug candidates for heart and metabolic conditions and neuropathic pain, and sells an approved heart-failure medicine to wholesalers.

How Do They Make Money?

Wholesalers and limited retail pharmacies buy INPEFA, and Lexicon earns the sale when it delivers the drug. Licensees pay upfront and at milestones, with additional royalties on sales.

revenue
SegmentShareRevenue
Product
Sold outright
9.4%
License
Licensed

91%

Who Are Their Customers?

Lexicon sells INPEFA mainly to major and selected regional wholesalers, which resell it to retail pharmacies, hospitals, government agencies and other institutions; it also sells to limited retail pharmacies and uses a mail-order pharmacy to dispense the drug.

Do Revenues Turn Into Profits?

No. It lost $50.3M in FY2025.

Operating income, FY2025
−98% of revenue
▲ +75% (Loss) vs FY2024 (−$197.1M, −634%)
Net income, FY2025
−101% of revenue
▲ +75% (Loss) vs FY2024 (−$200.4M, −645%)
Free cash flow, FY2025
−136% of revenue
▲ +62% (Loss) vs FY2024 (−$179.8M, −579%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −21%
vs $14.2M in Q3 FY2025
Net income
▼ −10% (Loss)
vs −$12.8M in Q3 FY2025
License share of net product revenue vs 92.9% in Q3 FY2025

Growing. Revenue grew 167.1x in 4 years, from $298K in FY2021 to $49.8M in FY2025, about 260% a year.

Revenue over time
Product License
$50M$25M$0

Who Do They Compete With?

Competes with Bristol Myers Squibb, Cytokinetics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Vertex, Novo Nordisk, Novartis, and Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support